In this article, we will look at some of the best penny stocks in the life sciences sector that currently offer attractive upside potential for investors.
On March 11, CBRE shared an analysis covering the U.S. market trends in life sciences real estate. The analysis reviewed the factors behind the recovery process in the life sciences real estate, which had been suffering from oversupply, risk aversion, and inactivity in the capital markets for two years. The analysis should not be ignored by investors who follow this market segment.
The major takeaway was that construction activity is expected to hit its 10-year low point, characterized by lower lab and R&D construction. This would eventually reduce pressure across the U.S. life sciences segment, and most importantly, would lead to improved fundamentals. Several positive trends were noted by CBRE at the end of 2025, with even greater improvement expected in 2026, indicating a change in the business cycle. The firm also pointed out some positive developments in both the stock market and venture capital investments, which typically precede an increase in the demand for laboratories, before entering 2026.
Investments in laboratory facilities have never been higher, underscoring the country’s reputation as a leader in life sciences worldwide. Investors, according to CBRE, can expect irregular demand trends because of the historically high patent cliff, fast-tracked drug approvals, diversified funding sources, and China’s growing importance in global R&D.
With that background, let’s explore our 8 Best Life Sciences Penny Stocks to Buy.
Tonhom1009/Shutterstock.com
Our Methodology
To identify relevant stocks for this article, we conducted a screening of U.S.-listed life sciences penny stocks with market capitalizations above $200 million. Also, we only shortlisted names with at least 20% upside potential according to analyst consensus, as of April 8 closing. Finally, we selected 8 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Nautilus Biotechnology Inc. (NASDAQ:NAUT)
Nautilus Biotechnology Inc. (NASDAQ:NAUT) is one of the 8 Best Life Sciences Penny Stocks to Buy.
On March 18, Nautilus Biotechnology Inc. (NASDAQ:NAUT) announced Baylor College of Medicine as the first customer of Nautilus’s Iterative Mapping Early Access Program. Baylor will be utilizing the Nautilus single-molecule proteomics technology through a National Institutes of Health U01 grant, which will allow Baylor to address one of the fundamental problems in cancer biology research. This involves understanding the roles of altered protein isoforms in promoting tumor growth, metastasis, immune escape, and drug resistance.
As Nautilus increases its commercial availability by using its validated tau proteoforms assay, Baylor will focus on creating innovative methods for detecting proteins. In the research study, Baylor will focus on creating a user-friendly computational tool kit with better detection capabilities of protein isoforms from traditional shotgun proteomics data sets.
Through the combination of computational techniques with high-resolution, full-length protein isoform profiling data sets generated using the Nautilus Voyager platform, this research project is expected to allow researchers to directly compare changes between transcriptional and proteomic events at an unprecedented level of detail.
Nautilus Biotechnology Inc. (NASDAQ:NAUT) is involved in the development of a technological platform for quantifying and unlocking the complexity of the proteome. Its platform offers end-to-end solutions involving reagents, consumables, and more. Its portfolio also includes optical imaging systems, single-molecule library kits, affinity reagents, and flow cells.
7. Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is one of the 8 Best Life Sciences Penny Stocks to Buy.
As of the April 8 close, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) had a moderately bullish consensus sentiment. The stock received coverage from 6 analysts, 3 of whom assigned Buy ratings and 3 gave Hold calls. With no Sell rating, the stock has a projected median 1-year price target of $4, which leads to an upside potential of more than 30%.
On March 26, the news portal Ad Hoc News reported that Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) had been exhibiting volatility amid trading activity in the stock options, as well as rating downgrades by some analysts. This reflects on investor skepticism at a time when the company aims for cost reduction and turning EBITDA positive during the ongoing year.
In late February, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) stated in its forecast of 2026 earnings that total revenue was expected to range between $200 million and $210 million for the upcoming year. This represents growth between 8% to 13% when compared to 2025 revenue levels. TriLink and Cygnus were projected to record a low single-digit growth rate for the same year.
The target range for the full year 2026 adjusted EBITDA of the company was set at $18-$20 million, along with 120% increase in gross margins compared to the prior year. As per the firm’s Chief Financial Officer, Rajesh Asarpota, operating expenses for the company would be reduced by approximately 13%. It has been revealed that general and administrative expenses will fall by about 18%, and sales and marketing expenses will witness a reduction of about 13%, while there will be an increase in research and development costs.
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) offers products that help with developing therapeutics, gene therapies, vaccines, and diagnostics. The company is engaged in the production and sales of oligonucleotide therapy and CleanCap capping technology, as well as the production of analytical products used in the biologic manufacturing process. It caters to biopharmaceutical and scientific research companies, and more.
6. Evotec SE (NASDAQ:EVO)
Evotec SE (NASDAQ:EVO) is one of the 8 Best Life Sciences Penny Stocks to Buy.
On March 10, Evotec SE (NASDAQ:EVO) announced Horizon, the follow-up phase in its multi-stage transformation initiative. The Horizon operating model embodies its evolution in the adoption of a new, focused operating model that comprises three elements, i.e., operation, science, and commercial execution.
This new Horizon operating model is aimed at delivering above-market growth and leveraging operations in an environment of normalized demand expectations. Moreover, it will ensure higher standards of scientific and operational performance based on the Priority Reset in 2024 and the mid-term value creation approaches outlined in 2025.
Horizon will streamline its corporate structure, with the realignment of Evotec’s worldwide experience through Centers of Excellence, as well as the appropriate positioning of Evotec’s footprint. The plan envisages optimization of the company’s footprint from 19 locations in 2024 to 14 locations in 2025 to 10 locations within the next two years. This process will be complemented by workforce restructuring up to 800 positions.
According to Evotec CEO Dr. Christian Wojczewski, Horizon marks the next stage in Evotec’s structured transformation journey, enabling the organization to become ready for sustainable, high-quality growth. He stated:
“Horizon represents the next step in Evotec’s structured transformation to position the company for sustainable, high-quality growth. Following the disciplined cost actions implemented over the past two years and the strategic priorities we set in 2025, we are now transforming our operating model. This will enable deeper integration, faster decision making and greater agility for our customers and partners. Horizon positions Evotec for stronger performance through 2027 and lays the foundation for further optimization and intelligent scaling toward 2030.”
Evotec SE (NASDAQ:EVO) is engaged in the research and development of therapeutics. The company offers pharmaceutical products for various healthcare sectors, including oncology, autoimmune, and respiratory, to name a few. It has collaboration agreements with several hospitals and universities, including Mass General Brigham, Harvard, Yale, and more.
While we acknowledge the potential of EVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EVO and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Life Sciences Penny Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
